{"id":"NCT01787799","sponsor":"Boston Scientific Corporation","briefTitle":"EVOLVE II QCA: A Prospective, Multicenter Trial to Assess the SYNERGY Stent System for the Treatment of Atherosclerotic Lesion(s)","officialTitle":"EVOLVE II QCA: A Prospective, Multicenter Trial to Assess the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System (SYNERGY Stent System) for the Treatment of Atherosclerotic Lesion(s)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-03","primaryCompletion":"2014-08","completion":"2014-10","firstPosted":"2013-02-11","resultsPosted":"2016-03-16","lastUpdate":"2016-03-16"},"enrollment":100,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Atherosclerotic Lesion(s)"],"interventions":[{"type":"DEVICE","name":"SYNERGY","otherNames":[]}],"arms":[{"label":"SYNERGY Stent System","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate 9 month angiographic and intravascular ultrasound (IVUS) data for the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System (SYNERGY Stent System) in the treatment of subjects with atherosclerotic lesion(s) ≤34 mm in length (by visual estimate) in native coronary arteries ≥2.25 mm to ≤4.0 mm in diameter (by visual estimate).","primaryOutcome":{"measure":"In-stent Late Loss","timeFrame":"9 month","effectByArm":[{"arm":"SYNERGY Stent System","deltaMin":0.23,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":21},"locations":{"siteCount":13,"countries":["Australia","Japan","New Zealand","Singapore"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":38,"n":100},"commonTop":["Myocardial Infarction","Catheter site haematoma","Adverse drug reaction","Non-cardiac chest pain","Headache"]}}